This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Chemed (CHE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ADUS vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Why Growth Investors Shouldn't Overlook Chemed (CHE)
by Zacks Equity Research
Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
Chemed (CHE) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -1.26% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
by Zacks Equity Research
Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.
Chemed (CHE) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Chemed (CHE) Q1 Earnings Miss Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care
by Zacks Equity Research
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
Centene (CNC), Pearl Health Unite to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.
Here's Why You Should Add Cigna (CI) Stock to Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.